Unthinkable? Reports That AZ May Spin Off China Ops Amid Geopolitical Risks

Competing Pressures, Deeper Localization

 
• By Brian Yang

AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.

China New Drug Approvals 2020
AZ reportedly to spin off its China subsidiary amid competing pressure, geoplitican tension • Source: Alamy

More from China

More from Focus On Asia